Company / PP&E per Share
UroGen Pharma Ltd. PP&E per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E per Share
$0.02
FY2025
5-year range
$0.02 / $0.09
FY2021-FY2025
Trend
-25.2%
vs FY2024
Sector context
#148 of 191
Health Care
What the data says
UroGen Pharma Ltd.'s pp&e per share of $0.02 is lower than 77% of companies in the Health Care sector (FY2025). PP&E per Share has declined for 5 consecutive years, from $0.10 in FY2020 to $0.02 in FY2025.
Based on SEC 10-K filings.
0.02 in FY2025 with a 5-year CAGR of -31.1%.
Declined from $0.03 to $0.02 over the past 2 years.
Health Care sector context is included.
PP&E per Share over time
Growth rates
- 3-Year CAGR
- -36.1%
- 5-Year CAGR
- -31.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 191This company $0.02 Sector average $22.34
▼
-99.9% below sector average
Key checks
Key Insights
- UroGen Pharma Ltd.'s pp&e per share has declined for 5 consecutive years.
- In FY2025, pp&e per share decreased 25.2% year-over-year.
- Ranks #148 out of 191 companies in the Health Care sector.
- Peak pp&e per share was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.02 | -25.2% |
| FY2024 | $0.02 | -32.3% |
| FY2023 | $0.03 | -48.4% |
| FY2022 | $0.06 | -34.9% |
| FY2021 | $0.09 | -8.8% |
| FY2020 | $0.10 | +61.5% |
| FY2019 | $0.06 | -12.6% |
| FY2018 | $0.07 | -16.8% |
| FY2017 | $0.08 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026